[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:attr-amyloidosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":93,"states":98},"ATTR Amyloidosis",13,10,[8,16,22,28,34,41,47,53,59,65,71,78,85],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07052903","TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",[12],"Phase 3","RECRUITING","2026-08-26T02:15:40.343619Z","2026-07-24T01:27:14.873535Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06128629","MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:26.677025Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant",[12],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.758438Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT05577819","Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF",[],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:26.768402Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT05758493","Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis",[38],"Phase 2","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.513821Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05489549","Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers",[],"2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.803246Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07358078","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting",[],"2026-08-26T02:18:03.638950Z","2026-05-13T02:55:06.695928Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis",[],"2026-08-26T02:18:47.742071Z","2026-05-13T02:55:06.492424Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06355934","OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis",[],"2026-08-26T02:17:54.420226Z","2026-05-13T02:55:06.483773Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis",[],"2026-08-26T02:15:52.238965Z","2026-05-13T02:55:06.402716Z",{"nct_id":72,"title":73,"phases":74,"status":75,"updated_at":76,"content_modified":77},"NCT07591038","PET\u002FCT Imaging in Carriers of TTR Mutations",[],"NOT_YET_RECRUITING","2026-08-26T02:15:15.642947Z","2026-05-29T15:36:40.201332Z",{"nct_id":79,"title":80,"phases":81,"status":82,"updated_at":83,"content_modified":84},"NCT06679946","A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:17:40.683658Z","2026-06-16T05:54:07.765794Z",{"nct_id":86,"title":87,"phases":88,"status":90,"updated_at":91,"content_modified":92},"NCT05489523","Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation",[89],"Phase 4","ACTIVE_NOT_RECRUITING","2026-08-03T03:03:50.544633Z","2026-05-05T02:43:28.337806Z",[94],{"biomarker":95,"count":96,"slug":97},"TTR Gene",3,"ttr-gene",[99,103,106,109,113,116,119,123,126,129,132,135,138,141,145,148,151,154,157,160,163,166,169,172],{"state":100,"count":101,"slug":102},"Massachusetts",8,"massachusetts",{"state":104,"count":101,"slug":105},"New York","new-york",{"state":107,"count":101,"slug":108},"Texas","texas",{"state":110,"count":111,"slug":112},"California",7,"california",{"state":114,"count":111,"slug":115},"Minnesota","minnesota",{"state":117,"count":111,"slug":118},"Ohio","ohio",{"state":120,"count":121,"slug":122},"District of Columbia",5,"district-of-columbia",{"state":124,"count":121,"slug":125},"Illinois","illinois",{"state":127,"count":121,"slug":128},"Maryland","maryland",{"state":130,"count":121,"slug":131},"Missouri","missouri",{"state":133,"count":121,"slug":134},"North Carolina","north-carolina",{"state":136,"count":121,"slug":137},"Oregon","oregon",{"state":139,"count":121,"slug":140},"Pennsylvania","pennsylvania",{"state":142,"count":143,"slug":144},"Connecticut",4,"connecticut",{"state":146,"count":143,"slug":147},"Florida","florida",{"state":149,"count":143,"slug":150},"Indiana","indiana",{"state":152,"count":143,"slug":153},"South Carolina","south-carolina",{"state":155,"count":143,"slug":156},"Virginia","virginia",{"state":158,"count":96,"slug":159},"Georgia","georgia",{"state":161,"count":96,"slug":162},"Michigan","michigan",{"state":164,"count":96,"slug":165},"New Jersey","new-jersey",{"state":167,"count":96,"slug":168},"Tennessee","tennessee",{"state":170,"count":96,"slug":171},"Utah","utah",{"state":173,"count":96,"slug":174},"Washington","washington"]